What is Precigen?
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company dedicated to pioneering gene and cell therapies. Leveraging precision technology, the company targets complex diseases across critical areas including immuno-oncology, autoimmune disorders, and infectious diseases. Precigen operates through two primary segments: Biopharmaceuticals, which focuses on its core therapeutic pipeline, and Exemplar, likely involved in platform development or specific therapeutic applications. The company's approach aims to deliver highly targeted and effective treatments for unmet medical needs.
How much funding has Precigen raised?
Precigen has raised a total of $129.4M across 1 funding round:
Stock Offering
$129.4M
Stock Issuance/Offering (2021): $129.4M, investors not publicly disclosed
What's next for Precigen?
The substantial enterprise-level funding and recent strategic investment indicate a strong validation of Precigen's technological platform and therapeutic pipeline. This capital infusion is expected to accelerate the company's clinical development programs, potentially enabling further expansion into new disease indications and the advancement of its lead candidates through late-stage trials. The strategic nature of the recent financing suggests potential collaborations or partnerships that could enhance market access and commercialization efforts, positioning Precigen for significant growth in the competitive biopharmaceutical landscape.
See full Precigen company page
